What Peptides Are
Peptides are short chains of amino acids derived from proteins. They tend to act like targeted keys for specific cellular receptors, unlike many small molecule drugs that affect multiple systems.
The FDA silently banned 19 peptides overnight, now RFK Jr is reversing it all. Dr Alex Tatem reveals the truth behind the cover-up, and what peptides can really do for your body. Dr. Alex Tatem is an internationally recognised urologist who has studied peptides for 12 years and runs a men’s health clinic. He also hosts a YouTube channel dedicated to demystifying peptides and men's health. In this explains: ◼ What peptides are, how they work, and which ones target your health problem ◼Why the peptide industry is quietly approaching the size of the entire AI sector ◼ Why male fertility is collapsing globally and what's silently driving it ◼ What low testosterone is doing to your body and how to fix it ◼ Why 30 million men with erectile dysfunction are never told about the most effective fix 00:00 Intro 00:03:15 What Exactly Is A Peptide—and Why It Matters More Than You Think 00:05:14 The “Lock” Explained: How Peptides Actually Work In Your Body 00:08:34 Why Peptides Are Suddenly Everywhere (And What Changed) 00:11:09 The Real Role Of Compounding Pharmacies—And Why They’re Controversial 00:17:16 Are Pharma Companies Prioritizing Profits Over Patients? 00:20:22 Why Peptides Are Back After Being Banned—What Happened Behind The Scenes 00:20:56 The Most Shocking Patient Transformation From Peptides 00:22:26 When You Should (And Shouldn’t) Use Peptides In Your Life 00:24:28 The Latest FDA Update: What It Means For Peptide Access 00:26:05 How People Are Actually Getting “Illegal” Peptides 00:27:41 How To Take Peptides Safely—What Most People Get Wrong 00:29:38 Why Big Pharma Feels Threatened By Peptides 00:33:53 The Exact Peptides Alex Uses—And His Reasons Why 00:37:49 How Peptides Could Transform Your Insulin Levels 00:38:42 Do Peptides Work As Creams? What You Need To Know 00:40:30 How Peptides May Unlock Better Cognitive Performance 00:42:58 The Future Of Muscle Retention On GLP-1s—What’s Coming Next 00:48:03 Ads 00:49:05 The Hidden Trade-Offs Of Peptides No One Talks About 00:52:09 The Real Benefits Of Different Peptides—And How They Compare 00:57:30 The Peptide That Could Change Your Sleep Quality 01:01:58 What Happens When You Stop Taking GLP-1s? 01:05:40 Ads 01:07:33 Is There A “Super Peptide” For Anti-Aging? 01:11:04 The Truth About Peptides And Erectile Dysfunction 01:11:56 Why Medicine Burned Me Out—And What It Reveals About The System 01:18:57 The Enhanced Games Explained—And Why They’re So Controversial 01:22:46 How To Improve Erections—What Actually Works Enjoyed the episode? Share this link and earn points for every referral - redeem them for exclusive prizes: https://doac-perks.com Independent Research Document: https://stevenbartlett.com/wp-content/uploads/2026/04/DOAC-Alex-Tatum-Independent-Research-Further-Reading.pdf Follow Dr Alex: X - https://link.thediaryofaceo.com/DS0mGd3 Instagram - https://link.thediaryofaceo.com/36mqqnE YouTube - https://link.thediaryofaceo.com/4SagDuv Website - https://link.thediaryofaceo.com/5WRUIrQ The Diary Of A CEO: ◼️Join DOAC circle here - https://doaccircle.com/ ◼️Buy The Diary Of A CEO book here - https://smarturl.it/DOACbook ◼️The 1% Diary is back - limited time only: https://bit.ly/3YFbJbt ◼️The Diary Of A CEO Conversation Cards (Second Edition): https://g2ul0.app.link/f31dsUttKKb ◼️Get email updates - https://bit.ly/diary-of-a-ceo-yt ◼️Follow Steven - https://g2ul0.app.link/gnGqL4IsKKb
Peptides are short chains of amino acids derived from proteins. They tend to act like targeted keys for specific cellular receptors, unlike many small molecule drugs that affect multiple systems.
The discussion contrasts broad acting small molecules with more selective peptide signaling. The promise is targeted effects with fewer off target side effects, although evidence quality varies by compound.
Insulin is highlighted as an early peptide therapy first used in 1921. Later examples like leuprolide show how peptides can be designed for specific endocrine control.
The guest emphasizes tolerance signals like difficulty establishing toxic dose thresholds in some studies. He also stresses that lack of large human trials limits certainty even when early signals look reassuring.
Peptides gained attention through social media, especially short form content. The conversation also frames a forbidden fruit effect after regulatory restrictions increased curiosity and demand.
A Supreme Court decision about patenting natural human genes is presented as reducing incentives to develop non patentable biologic compounds. The argument is that expensive trials are harder to justify without strong exclusivity.
Compounding is described as customized medication preparation for patients who do not fit standardized dosing. Modern compounders are portrayed as scaled industrial operations that can tailor formulations under specific rules.
The guest describes an FDA framework that classifies substances into categories for compounding eligibility. He claims many popular peptides moved into a restricted category in 2023, leading to abrupt loss of access.
Officially the rationale is described as insufficient safety data without full FDA approval. The guest also suggests economic incentives and industry pressure could have influenced enforcement and decisions.
Several peptides are name checked for skin, sleep, tanning, sexual function, muscle signaling, and healing. The episode presents them as a broad toolbox, while repeatedly noting trade offs and uncertainty.
MK-677 is discussed as an oral small molecule that stimulates ghrelin receptors to increase growth hormone release. It is framed as useful for appetite and cachexia contexts, while being swept into similar regulatory scrutiny.
Semaglutide and tirzepatide are presented as transformative for weight loss and insulin resistance by slowing gastric emptying and reducing intake. A fertility improvement story is attributed to weight loss enabled by tirzepatide and lifestyle changes.
The guest uses an apps analogy to explain how peptides can be designed for many narrow functions. The framing is that new peptide development could rapidly expand options across health domains.
A press release is referenced about a July review to consider moving seven peptides back into a compounding eligible category. Examples mentioned include BPC-157, TB-500, CJC related compounds, epithalon, and cognitive or sleep related peptides.
After restrictions, the episode describes a shift to products labeled for research to avoid FDA oversight. The key concern is inconsistent purity and dosing, which is compared to risky food choices with unknown quality control.
Most peptides are described as broken down in the gut like dietary protein, making oral use ineffective. As a result, many are taken via subcutaneous or intramuscular injection, with a few noted exceptions.
Auto injector pens are portrayed as convenient and standardized. Vial based dosing is portrayed as flexible for microdosing and side effect control, but it requires careful calculation and sterile technique.
The guest argues compounded versions can differ enough to allow customization, but still face intense enforcement pressure. He frames this as a competition issue between compounders and major manufacturers.
The guest says he only uses low dose tirzepatide currently. He cites lack of a safe legal framework as the reason he avoids other peptides and says he wants to model compliant behavior for patients.
GHK-Cu is described as a copper peptide used topically to support collagen and elastin related skin quality. It is framed as more accessible due to different regulation for creams compared with injectables.
Semax is discussed as a short peptide studied for recovery after brain injury and stroke contexts. Intranasal delivery is presented as a way to reach relevant tissues through mucosal absorption.
DSIP and epithalon are discussed in relation to sleep regulation and circadian rhythm support. The guest is skeptical of dramatic longevity claims but suggests circadian effects are a more plausible target.
These are presented as synergistic tools to stimulate natural growth hormone release. Claimed effects include recovery support, fat loss, and skin and hair changes, with cautions about glucose impacts and misuse.
High or prolonged dosing is linked to insulin resistance and acromegaly like changes in facial bone structure. Cancer progression is raised as a theoretical concern, along with joint swelling and numbness symptoms.
Tesamorelin is described as a commercially available peptide used for reducing abdominal or visceral fat. The conversation stresses that stopping therapy without lifestyle changes can lead to rebound toward baseline.
Melanotan II is described as inducing tanning with minimal UV exposure and also affecting sexual function. PT-141 is described as a prescription option focused on sexual benefits without tanning.
Retatrutide is described as a triple agonist targeting GLP-1, GIP, and glucagon pathways. It is framed as producing strong weight loss and liver health improvements, with the guest predicting major commercial significance.
The episode warns that aggressive calorie deficits can reduce muscle as well as fat. Maintaining muscle is framed as crucial for metabolic health, and splitting doses is discussed as a way to reduce GLP-1 side effects.
Monoclonal antibody myostatin pathway inhibitors are discussed as a future approach to prevent muscle breakdown during weight loss. Several candidates are named as being in development and positioned as a complement to GLP-1 therapy.
A recurring theme is that every intervention has downsides, especially when sourcing is unregulated. The biggest practical trade off discussed is uncertainty about product identity, contamination, and correct dosing.
The guest urges focusing on the health problem first rather than chasing a trendy compound. He recommends clinician guided decisions and avoiding research labeled products due to quality and safety uncertainty.
The conversation says weight regain is common after stopping if lifestyle does not change. It also notes some people may maintain results with lower maintenance dosing combined with behavior changes.
The episode connects obesity and insulin resistance to worsening sperm parameters in men. It argues that effective metabolic interventions could indirectly improve fertility trends alongside environmental concerns like microplastics.
He describes a specialized focus on low testosterone management, erectile dysfunction, Peyronie’s disease, male fertility, and post prostate cancer urinary issues. The patient advocacy framing ties these problems to vascular and metabolic health.
The guest recounts grueling surgical training and an emotionally intense complication experience. He links his later health focus to wanting to better support patients and be present as a parent and partner.
He shares that he and his wife needed IVF when trying to conceive. That experience is described as shaping his empathy for patients dealing with infertility and hormonal dysfunction.
The Enhanced Games concept is discussed as allowing performance enhancing drug use with medical oversight. The episode contrasts this with current doping realities, athlete pay issues, and the potential for record breaking incentives.
The guest explains advanced erectile dysfunction as an end stage vascular problem when pills fail. He describes inflatable penile implants as internal hydraulic devices that restore function without changing sensation, with large unmet demand.